Base Therapeutics (shanghai) Co., Ltd.
Clinical trials sponsored by Base Therapeutics (shanghai) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cell therapy takes on Hard-to-Treat cancers Results expected Jun 2027 (estimated)
- Engineered immune cells take on Drug-Resistant lung cancer in first human trial Results expected Jul 2027 (estimated)
-
Engineered immune cells take on Drug-Resistant lung cancer in first human trial
Disease control Recruiting nowThis early-phase study tests a new cell therapy called NK510 in 12 people with advanced non-small cell lung cancer that no longer responds to PD-1 inhibitors. The treatment uses specially designed natural killer cells that are blocked from a protein called TIGIT, aiming to boost …
Early phase 1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Engineered immune cells take on Cancer-Related fluid swelling
Disease control Recruiting nowThis early-phase trial is testing a new treatment called NK521 for people with advanced solid tumors that have spread and caused fluid buildup in the belly (malignant ascites). The treatment uses a person's own natural killer (NK) cells that have been gene-edited to better attack…
Early phase 1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC